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Summary 
Background 
Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of the commonest 
neurosurgical procedures worldwide. Shunt infection affects up to 15% of patients, resulting 
in long hospital admission, multiple surgeries, reduced cognition and quality of life. The aim 
of this trial was to determine the clinical and cost-effectiveness of antibiotic (rifampicin and 
clindamycin) or silver shunts compared to standard shunts at reducing infection. 
 
Methods 
Patients with hydrocephalus of any aetiology, undergoing insertion of their first 
ventriculoperitoneal shunt were randomised (1:1:1) to receive standard, antibiotic or silver 
shunts. Twenty-one neurosurgery units in the UK and Ireland participated. Primary outcome 
was time to shunt failure due to infection. Secondary outcomes were time to shunt removal 
for suspected infection, shunt failure of any cause, reason for failure (infection, mechanical), 
types of shunt infection, time to infection following first clean revision and cost-
effectiveness. Outcomes were analyzed by intention-to-treat. [ISRCTN49474281]. 
 
Findings 
Between June 26, 2013 and Oct 9, 2017, 1605 patients, from neonate to 91 years of age, 
were randomised to 536 standard, 538 antibiotic, and 531 silver shunts. Infection occurred 
in 6·0% of standard, 2·2% of antibiotic and 5·9% of silver shunts. Compared to standard, 
antibiotic shunts were associated with lower rates of infection (cause specific Hazard Ratio 
(csHR) [97.5% confidence interval]: 0·38, [0·18, 0·80], p<0·01) and (subdistribution Hazard 
Ratio, sHR 0·38 [0·18, 0·80], p<0·01). Silver shunts were not associated with lower rates of 
infection compared to standard (csHR: 0·99, [0·56, 1·74], p<0·96). The shunt failure rate due 
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to any cause was 25·0% overall and did not differ between groups. Antibiotic shunts save 
£135,753 per infection avoided. 
 
Interpretation 
Antibiotic ventriculoperitoneal shunts have a reduced infection rate compared to standard 
shunts, whereas silver shunts do not. Antibiotic shunts are cost saving. 
 
Funding 
This study was funded by the National Institute for Health Research Health Technology 
Assessment programme under grant agreement 10/104/30. 
 
Disclaimer 
The views expressed are those of the authors and not necessarily those of the NHS, the NIHR 
or the Department of Health and Social Care. 
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Introduction 
Hydrocephalus affects one in every five hundred births.1 It also affects older children and 
adults of all ages and can be secondary to a variety of causes including haemorrhage, 
trauma, infection and intracranial tumours.2 A recent systematic review and meta-analysis 
reported the hydrocephalus prevalence to be 88/100,000 in children, 11/100,000 in adults 
and 175/100,000 in the elderly.3  The commonest treatment for hydrocephalus is the 
ventriculoperitoneal shunt, which comprises proximal (ventricular) and distal (peritoneal) 
silicone catheters joined by a valve to drain cerebrospinal fluid (CSF) from the ventricles into 
the peritoneal cavity. Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of 
the commonest neurosurgical procedures worldwide.4  Failure of this shunt due to infection 
occurs in 7-15% of patients.5,6 Episodes of infection have a major impact on patients, require 
prolonged hospitalization and antibiotics, surgery to remove the infected shunt and to place 
a new shunt once the infection has been treated. Shunt infection impacts on health-related 
quality of life, cognitive function,7 and survival, with the number of infections being an 
independent predictor of death.8 
 
Impregnated shunt catheters have been introduced as a means to reduce infection in 
addition to the usual surgical site infection prevention care bundles. There are three types of 
shunt catheter: standard, antibiotic impregnated (0.15% clindamycin and 0.054% rifampicin) 
and silver impregnated. Systematic reviews and meta-analyses did not find any high quality 
evidence to support their comparative effectiveness at reducing shunt infection9,10. 
Consequently, practice is variable across the world, with selection based on neurosurgeon 
preference and costs. 
 
We conducted the British Antibiotic and Silver Impregnated Catheters for 
ventriculoperitoneal shunts multi-center randomised controlled trial (BASICS) to assess the 
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clinical and cost-effectiveness of antibiotic and silver shunts at reducing shunt failure due to 
infection, compared to standard shunts in patients undergoing insertion of their first 
ventriculoperitoneal shunt for hydrocephalus. 
 
 
Methods 
Study design 
In this parallel, multi-centre randomised controlled trial we compared standard, antibiotic 
and silver shunts in patients undergoing insertion of their first ventriculoperitoneal shunt for 
hydrocephalus. Trial sites were twenty-one regional adult and paediatric neurosurgery 
centers in the United Kingdom and Republic of Ireland (See Section 1 of the Supplementary 
Appendix). Ethics approval was obtained from the North West Greater Manchester research 
ethics committee (ref: 12/NW/0790). The trial protocol (available at 
www.journalslibrary.nihr.ac.uk/programmes/hta/1010430/#/) has been published 
previously11 (Substantial amendments are detailed in Section 6 of the Supplementary 
Appendix). 
 
Participants 
To undergo randomisation in the trial, patients could be any age, and have hydrocephalus of 
any aetiology requiring a first ventriculoperitoneal shunt. Patients with failed primary 
endoscopic third ventriculostomy, previous indwelling external ventricular drain and 
indwelling ventricular access device were included. Patients were excluded if they had 
evidence of active and on going CSF or peritoneal infection, a previous indwelling 
ventriculoperitoneal shunt, multi-loculated hydrocephalus requiring multiple shunts or 
neuro-endoscopy, known allergy to rifampicin, clindamycin or silver, or if a ventriculo-atrial 
or ventriculo-pleural shunt was planned. Patients gave written informed consent or assent 
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for minors as appropriate. Consent for adults lacking capacity was obtained from a 
consultee, usually the next of kin, or an independent healthcare professional, and it was 
later sought again from the participant once capacity was regained. 
 
Randomisation 
Patients were randomised to standard, antibiotic or silver shunts at a ratio of 1:1:1 in 
random permuted blocks of 3 and 6. The randomisation sequence was generated by an 
independent statistician, and stratified by neurosurgical unit and age group (adult or 
paediatric, defined according to unit practice). The randomisation was revealed in the 
operating theatre at the time the shunt was required using opaque tamper-proof sealed 
envelopes that were opened by tearing perforated edges. Due to the different colour of the 
shunts it was not possible to blind the neurosurgeon and operating staff. Shunt type was not 
recorded in the operating record and was not disclosed outside the operating room. Training 
on non-disclosure of shunt type was provided to all investigators. All shunt types were used 
in accordance with the manufacturer’s instructions for their intended purpose. Patients 
were blind to the type of shunt inserted. 
 
Procedures 
Data were collected at baseline; randomisation (pre-operative assessment); 
randomisation (first surgery); early post-operative assessment; first routine post 
operative assessment; 12 weekly follow up assessments; subsequent routine post 
operative assessments; and, where applicable, unscheduled visits/admissions and at 
shunt revision/removals (see section 2 of supplementary material). All patients 
received prophylactic antibiotics at the time of shunt insertion as per standard 
neurosurgical practice. All other parameters related to surgical shunt insertion 
technique e.g. choice of skin preparation, hair shave or not, number and seniority of 
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neurosurgeon, position on operating list were recorded but not standardised and were 
undertaken according to each participating neurosurgery unit’s practice. Patients were 
followed for a minimum 6 months and maximum 2 years. 
 
Outcomes 
The primary outcome was time to shunt failure due to infection as assessed by a blinded 
central review panel comprised of the Chief Investigator [CLM] (or delegate for participants 
treated by the chief investigator [MDJ]) and trial microbiologist [JCH], masked to allocations. 
At first shunt revision, sites recorded data on clinical presentation (e.g. temperature, 
headache, lethargy, meningism, conscious level, wound erythema), peripheral white blood 
cell count, C-reactive protein (CRP), microbiology analysis of CSF (microscopy and culture), 
and treatment initiated (e.g. antibiotics prescribed, shunt removed).  Based on these 
parameters the shunt failure was classified as being due to infection or not.  Shunt infections 
were further defined as: (1) Definite – culture positive: growth of organisms from CSF on 
primary culture or repeated (>1) subculture [the passage [growth identified following 
enrichment of cells from the primary culture to fresh medium by overnight broth 
incubation], with or without clinical signs of infection, and managed by shunt removal and 
antibiotic treatment; (2) Probable – culture uncertain: growth of organisms from CSF on one 
subculture only, with or without clinical signs of infection, with CSF pleocytosis and/or 
organisms on gram stain, and managed by shunt removal and antibiotic treatment; (3) 
Probable – culture negative: no organisms growth but, with or without clinical signs of 
infection, with CSF pleocytosis and/or organisms on gram stain, and managed by shunt 
removal and antibiotic treatment; (4) Possible – culture uncertain: no signs of infection, no 
CSF pleocytosis, no organisms seen on gram stain, growth after enrichment in one CSF 
sample only, and managed by shunt removal and antibiotic treatment; and (5) Shunt deep 
 10 
incision infection: infection of the deep surgical wound and subcutaneous shunt without any 
evidence of CSF infection. 
 
Secondary outcomes were: time to removal of the first shunt due to suspected infection, as 
defined by the treating neurosurgeon at the time of first revision; time to shunt failure of 
any cause; reason for shunt failure (infection, mechanical [blockage of any component i.e. 
valve or catheters], patient [unrelated medical condition e.g. appendicitis], functional 
[change of valve for symptomatic over- or under-drainage of CSF e.g. fixed pressure to 
programmable valve] as classified by treating neurosurgeon); types of bacterial shunt 
infection [see table 2]; time to shunt infection following first clean revision as classified by 
central review; Quality of life measured using the Hydrocephalus Outcome Questionnaire12 
and health economic outcomes: incremental cost per shunt failure (any cause) averted and 
per quality-adjusted life (QALY) gained using the EQ-5D-3L, EQ-5D-3L (proxy) or EQ-5D-3L-Y. 
Data on complications and serious adverse events were collected (see protocol: 
www.journalslibrary.nihr.ac.uk/programmes/hta/1010430/#/). 
 
Statistical analysis 
A Trial Steering Committee, comprising a majority of independent members viewing reports 
blinded to treatment arm, and an Independent Data Monitoring Committee viewing 
unblinded reports reviewed the trial regularly to assess conduct, progress including rates of 
shunt infection, and safety. The sample size for the primary outcome used the method 
described by Pintilie13 with  the following assumptions: (i) failure for infection was the event 
of interest with all other reasons for failure a competing risk; (ii) the rate of infection was 8% 
in the standard shunt arm5 and 4% in the impregnated shunt (antibiotic or silver) arms; (iii) 
the competing risk event rate was 30%; and (iv) 5% loss to follow-up. Based on this a total 
sample size of 1200 with 119 events demonstrated good statistical power (88%) with 
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leverage for a lower event rate. An interim analysis was planned after 50% of the total 
events had been observed using Haybittle-Peto.14  Monitoring of the infection rates 
demonstrated the majority of events occur within one month of shunt insertion (i.e. was not 
exponentially distributed), and that the rates of infection, competing risk, and loss to follow 
up were lower than expected. The independent data monitoring committee reviewed the 
sample size calculations and recommended increasing recruitment to a target of 1606 with 
101 events to provide 80% power; the trial steering committee agreed. The early occurrence 
of events and assumption of exponential risk were managed in the Pintilie13 assumptions by 
reducing the accrual and follow up rates to one month. The analysis was conducted 
according to a pre-specified statistical analysis plan, which was updated following review of 
data by a statistician blind to comparative interim reports. Outcomes were analyzed 
according to the intention-to-treat principle and safety analyses according to the type of 
shunt in situ. To adjust for the three treatment arms, a p-value of 0·025 was considered 
statistically significant and 97.5% confident intervals (CI) were used throughout. Outcome, 
with shunt failure due to infection as the event of interest, used Fine and Gray15 survival 
regression models with cause specific hazard ratios (csHR) and subdistribution hazard ratio 
(sHR) presented.16,17  Cox regression models were used to analyse time to shunt failure of 
any cause. The assumption of proportionality for time to event outcomes was checked 
using Schoenfeld residuals. Reason for shunt failure is presented descriptively and with a 
chi-squared test. Types of organisms cultured from CSF are presented descriptively. Quality 
of life outcomes were analysed using mixed models for repeated measures. All survival 
models were adjusted for the age category of the recruiting site (paediatric or adult), with 
adult sites further categorised by age over 65 years. Age was used in preference to and 
recruiting centre due to prognostic value of age group and the dependency between age 
group and centre prevented inclusion of both covariates.  Primary outcome and safety 
analyses were validated by independent programming from the point of raw data 
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extraction. All analyses were done with SAS software version 9.4 with SAS/STAT package 
14.3. The trial was registered with ISCTRN: 49474281. 
 
Economic analysis 
The economic analysis (section 5 of the Supplementary Appendix) adopted the perspective 
of the National Health Service in the UK to estimate the incremental cost per first shunt 
failure (due to any cause) averted for antibiotic, silver and standard shunts. Within-trial 
healthcare resource use was based on responses to questionnaires, routine hospital data via 
Patient Level Information and Costing Systems, and entries in case report forms. Unit costs 
for 2016-17 were taken from standard sources (Tables S12-S14).18-21  Silver cost £361·62, 
antibiotic cost £384, and standard cost £172. In the base-case analysis, costs and outcomes 
incurred in the second year were discounted at a rate of 3·5%, and any missing data were 
multiply imputed using the method of chained equations. Total costs were analysed using 
linear regression with the stratifying variables, time in study, intervention group and 
treatment failure, as predictors. Mean outcome by intervention group was analysed in the 
same way, but with total cost substituting treatment failure. Sensitivity analyses considered 
(i) applying different discount rates (0%, 1·5% and 6% per annum for both costs and 
outcomes); (ii) using observed data for costs (no multiple imputation); and (iii) using a 
generalised linear model for analysing costs. Alternative forms of cost-effectiveness, and a 
cost-utility analysis relating to participants aged ≥5 years were also conducted. A stratified 
analysis was undertaken to estimate cost-effectiveness by age group - paediatrics, adults up 
to 65, and ≥65 years of age. 
 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding authors had full access to all the 
 13 
data in the study and had final responsibility for the decision to submit for publication. 
 
Results 
Between June 26, 2013 and Oct 9, 2017, there were 1606 randomisations. One patient 
was erroneously randomised twice and so data from the first randomization only were 
used (Figure 1). Fifty-three participants subsequently withdrew from follow-up (see 
Figure 1), of which 24 continued to provide routinely collected data. The characteristics 
of the three groups were similar at baseline (Table 1, Tables S4 and S5).  
1601 patients had a shunt inserted (99.8%) and 1585 received the allocated shunt 
(Figure 1) 98·8%, N=1605). Patients not receiving a shunt (n=4), or with an infection at 
insertion (n=7) were not included in the primary analysis set (Figure 1). The median 
follow-up time for patients assessed for primary outcome was 22 months (LQ - UQ; 10-
24; min to max 0 to 24, N=1594).  
398 patients had revision operations (25·0%, N=1594), with 75 being centrally classified 
as shunt infections (4·7%, Table 2). When compared to the standard shunt over time, the 
antibiotic shunt decreased the rate of shunt failure due to infection (csHR: 0·38, 97·5% CI: 
[0·18, 0·80], p<·01; Table 3). Silver was comparable to standard shunts (csHR: 0·99, 97·5% CI: 
[0·56, 1·74], p=0.96; Table 3). Figure 2 shows the cumulative incidence of failure due to 
infection by shunt group. The majority of centrally assessed infections were classified as 
definite – culture positive (53/75, 70·7%). 
 
Of the total 398 revisions, 78 (4·9%, Table 2) were defined by the treating neurosurgeon as 
due to suspected infection. Antibiotic but not silver shunts were associated with a significant 
decrease of failure due to infection when compared to standard shunts (Table 3). The reason 
for revision was classified by central review (primary outcome) and treating neurosurgeon 
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(secondary outcome) as infection or no infection, and this classification was the same in 
95·7% (381/398) of revisions (Table S6). 
 
Kaplan-Meier curves for time to shunt failure for any cause showed no significant difference 
between antibiotic or silver in comparison to standard shunts (Table 3, Figure S2). The 
number of shunt failures was similar between the three groups (Table 2), however the 
underlying reason differed when comparing standard to antibiotic shunts (p=0·02, Table S7) 
with fewer infections for antibiotic shunts but a higher frequency of failure due to other 
causes. 
 
Staphylococcus aureus (30%) and coagulase negative staphylococci (37·5%) accounted for 
the majority of cultured organisms (Table S8). Culture results show a reduction in 
staphylococcal/gram positive infections for antibiotic shunts compared to standard and 
silver. All three shunt types had a similar number of gram-negative infections. The 
proportion of culture positive infections was lowest in antibiotic shunts (50%), (compared to 
68·8% in standard and 80·6% in silver shunts). The remaining infections were classified as 
infection by the central review panel based on the CSF white cell counts, clinical features 
and blood parameters (Table 2).  
 
Following first clean (non-infected) revision (n=323), the proportion of patients with 
revisions for any reason (infection and no infection) increased to 39·6% (128/323; Table S9). 
This rate was 25% (398/1594) in de novo shunts (Table 2). The overall infection rate was also 
higher within this subgroup compared to de novo shunts 6·2% (20/323, Table S9) versus 
4·7% (75/1594, Table 2). There was no significant difference in time to infection following 
first clean revision when comparing either antibiotic or silver (Table 3) to standard shunts. 
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The proportion of revisions of first shunt for any cause (paediatric: 225/592, 38·0%; adults 
up to 65 years: 118/499, 23·6%; 65 years and over: 55/503, 10·9%, Table S10) and for 
infection (paediatric: 47/592, 7·9%; adults up to 65 years: 23/499, 4·6%; 65 years and over: 
5/503, 1·0%, Table S10) varied by participant age group. Compared to children, over time 
adults up to 65 years, and adults 65 or over had a significantly lower rate of shunt failure 
due to infection (adults under 65 csHR: 0·55, 97·5% CI: [0·31, 0·97], p=0·02; adults 65 or over 
csHR: 0·12, 97·5% CI: [0·04, 0·34], p<0·01; Table 3). Figures S3 and S4 display the cumulative 
incidence of time to shunt failure due to infection by age group and shunt stratified by age 
group respectively. Schoenfeld residuals supported the assumption of proportionality used 
in models of for time to event outcomes.  
 
The level of missing cost data was balanced across the three intervention groups (Table 
S15). Disaggregated resource use and costs are presented in Tables S16-S17. Mean total 
costs were £18,707 (97·5% CI: £13,888, £26,966) for standard shunts, £14,192 (97·5% 
CI: £12,450, £17,786) for antibiotic, and £17,385 (97·5% CI: £14,649, £22,355) for silver 
shunts (Table S18). Responses to EQ-5D are presented in Tables S19-S21. In the base-
case analysis, the total costs relating to both silver and antibiotic shunts were less than 
standard. Incrementally, silver shunts saved £62,358 for each additional first shunt 
failure due to any reason compared with standard; and antibiotic shunts saved 
£638,600 per additional failure in comparison to silver (Table S22). In sensitivity 
analyses, the incremental cost-effectiveness ratios were stable to changes in discount 
rate and choice of regression modelling but, based on observed data, antibiotic 
dominated silver shunts, and saved £56,771 for each additional failure compared with 
standard shunts. Antibiotic shunts were most cost-effective in paediatrics, with mean 
savings of £5,312 and 0·004 fewer shunt failures (Table S23). A cost-effectiveness 
analysis based on the incremental cost per infection averted indicated that silver shunts 
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were dominated by standard, whereas antibiotic shunts were dominant, saving £4,059 
per 0·030 fewer infection-related shunt failures (Table S24). There were insufficient 
data to formally analyse Hydrocephalus Outcome Questionnaires and results are 
therefore presented descriptively (Tables S25-S26). In the cost utility analysis, antibiotic 
shunts were dominated by silver. Compared with standard, silver shunts were £183 
more costly, and yielded 0·096 additional QALYs overall, resulting in an incremental 
cost-effectiveness ratio of £1,904 per QALY gained, and a probability of 0.52 of being 
cost-effective at £20,000 per QALY (Figure S5). 
 
There were no serious adverse events. A total 654 adverse events were reported in 413 
patients (25·8%, N=1601 who received a shunt). The proportion of patients experiencing an 
event was highest for silver shunts (Standard: 25·4%; Antibiotic: 23·3%; Silver: 36·4%, Table 
S11). Common adverse events were ventricular catheter obstruction (96 events in 79 
patients); shunt valve obstruction (65 events in 52 patients); and valve change for 
symptomatic over drainage (54 events in 50). All of these were expected events in the 
context of re-admission for shunt revision. 
 
Discussion 
In this trial of patients with hydrocephalus undergoing insertion of a first permanent 
ventriculoperitoneal shunt the infection rates were 6·0% for those receiving standard 
shunts, 2·2% for antibiotic shunts and 5·9% for silver shunts. Compared to standard shunts, 
antibiotic shunts were significantly associated with a lower rate of infection while no such 
effect was evident for silver shunts. This effect was present across all age categories. The risk 
of shunt infection was highest in children, reducing in adults and being particularly low in 
the elderly. There are significant economic benefits for every shunt infection averted. 
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The BASICS trial provides definitive evidence in the debate on use of using antibiotic or silver 
shunts to reduce infection. A previous randomised trial that was underpowered  compared 
antibiotic to standard shunts, but did not show a statistically significant difference in the risk 
of infection (relative risk: 0·38 CI: 0·11, 1·30; p=0·12).22  Additionally, systematic reviews and 
meta-analyses did not find any high quality evidence to support the comparative 
effectiveness of antibiotic shunts at reducing infection.9,10 Silver catheters have only been 
evaluated for use in temporary external ventricular drains, not permanent implanted shunts. 
A randomised trial of external ventricular drains (silver versus standard) reported a 
reduction in infection from 21·4% (30/140) to 12·3% (17/138) (p=0·042),23 although this is 
much higher than the UK national reported infection rate (9·3%).24 The BASICS trial was 
therefore conceived to evaluate both antibiotic and silver shunts, which might otherwise 
have been widely introduced into routine clinical practice despite a lack of firm evidence of 
their efficacy. The results of our trial show that antibiotic shunts are both clinically and cost 
effective and will inform neurosurgery practice and shunt choice for the benefit of patients. 
 
Correctly diagnosing shunt infection when the CSF is culture positive is straightforward, 
however this only applies to around 70% of cases. When the CSF is culture negative the 
treating neurosurgeon must consider other parameters including, CSF white cell count, 
clinical symptoms and signs and prior treatment with antibiotics. In these circumstances 
removal of the shunt and antibiotic treatment often leads to resolution of the presumed 
infection and patient recovery. The classification of shunt infection in our study was 
determined by the central review committee (table 2), and the proportion of culture positive 
infections was 68·8% in standard shunts, 50·0% in antibiotic shunts and 80·6% in silver 
shunts. There was a lower rate of culture positive infection with antibiotic shunts. Our 
analysis allowed for culture negative infections to be included when there was sufficient 
supporting clinical evidence of shunt infection. This was because we postulated that the 
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presence of antibiotic and possibly silver shunts might reduce the ability to culture 
organisms from infected shunts. Our study showed an even greater effect in favour of 
antibiotic shunts when only culture positive infections were analysed. The reduction of 
infections seen is consistent with the expected microbiological spectrum of the antibiotic 
shunts, which are especially active against gram-positive organisms, and were designed to 
prevent Staphylococcus species infection. The culture results show a large reduction in 
staphylococcal infection compared to standard and silver shunts, which accounts for the 
majority of the reduction. All three shunt types had a similar number of gram-negative 
infections supporting the biological plausibility of our results. 
 
It should be noted that the overall shunt failure rate was the same for all groups even 
though infection was reduced in antibiotic shunts. When one removes infection as a cause, 
the clean non-infected revision rates were slightly higher for antibiotic shunts. The cause is 
unclear but one hypothesis is that the antibiotic catheters may convert an ‘infected’ shunt 
revision into an apparently ‘clean’ shunt revision. This might occur because low virulent 
pathogens are restricted to a biofilm in the valve (which is not impregnated) that does not 
cause detectable changes in the CSF (such as increased white cell count) as there is no 
ventriculitis and the bacteria are low in number or not able to grow in the presence of the 
eluted antibiotics. However, changes in CSF composition and flow (such as debris or high 
protein) may lead to blockage of the intricate valve mechanism. Our study was not powered 
or designed to answer this question directly, but it will serve as a future important research 
question. Nevertheless, from the patient perspective, whilst mechanical shunt revision still 
requires surgery which may impact on their quality of life, the hospital admission is short, 
prolonged antibiotics are not required and patients recover more quickly with fewer long-
term neurological sequelae when compared to shunt infection.7,8 
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Complications associated with shunt failures are expensive to manage.25-27 Economic 
analyses suggest that the use of impregnated shunts that result in fewer complications, even 
if more expensive to purchase, could be cost-effective or yield cost savings.10,28,29 The cost-
effectiveness analysis within BASICS estimated that although antibiotic shunts are twice the 
price of standard, this upfront cost could be justified by the reduced infection rate and 
associated cost savings of further surgery and prolonged hospital care. Based on the primary 
economic outcome of incremental cost per shunt failure (due to any cause) averted, there 
appeared to be large potential savings for additional cases of shunt failures with silver and 
antibiotic compared to standard. This conservative estimate does not assume equivalence 
despite no difference between groups in shunt failure rates. Had a cost-minimisation 
analysis been considered appropriate, the saving per patient having an antibiotic rather than 
a standard shunt would be £4,515 (95% CI £433, £8,597). In this context, the secondary 
outcome based on the incremental cost per shunt infection averted is relevant. Compared 
with standard, silver shunts were dominated, but antibiotic shunts were dominant, saving 
£4,059 per 0·030 fewer infection-related failures; equating to £135,753 per infection 
avoided. The cost-utility analysis was limited with respect to missing data, and exclusion of 
participants who were at highest risk of shunt infections. 
 
The strengths of this study are that: (i) infections were centrally classified blind to treatment 
allocation thereby removing the risk of bias by the treating neurosurgeon; (ii) participant 
retention was very high due to the nature of the intervention and the primary outcome 
(patients with infected shunts are always re-admitted to hospital); (iii) patient withdrawal 
was low (n=53, 3·3%) so it is unlikely events were missed; (iv) participants were recruited 
across the whole of the UK and Republic of Ireland to encompass all ages and socio-
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economic classes; (v) the study samples size was large; and (vi) the results have wide 
generalizability because we did not mandate a specific surgical shunt insertion technique. 
 
Some limitations of the trial should be noted. First it was not possible to blind the treating 
neurosurgeon to the shunt type because the physical appearance of the shunts is distinctive. 
Shunt type was blinded to the patient and not recorded in the patient records. The majority 
of shunt revisions and removals for infection happen as emergencies and are managed by 
the emergency neurosurgery team. Therefore, the likelihood of the same neurosurgeon who 
inserted the shunt being involved in the decision to remove it was low given the work rotas 
of neurosurgical staff. Furthermore, classification of shunt infection between treating 
neurosurgeon and central assessment had high agreement (95·7%), suggesting that any 
bias that the treating neurosurgeon may have had did not impact the study conclusion. 
Second, ventriculoatrial and ventriculopleural shunts were excluded although we postulate 
the results are translatable to patients undergoing these procedures. Finally, the return rate 
for patient reported outcomes was low limiting the analysis of the impact of shunt infection 
on patients, and the reliability of the cost utility analysis. 
 
The BASICS study is the largest prospective randomised study for shunts in 
hydrocephalus worldwide. The study collected blood and CSF samples from participants 
that will be used for future research into biomarkers for infection and host response. 
Data on hydrocephalus aetiology, surgical techniques, types of valves and technology 
used will be analysed and used to will be analysed and used to develop 
recommendations and healthcare policy for patients undergoing insertion of 
ventriculoperitoneal shunts. 
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In conclusion, antibiotic shunts significantly reduce the infection rate and probability of 
infection compared to standard shunts in all age groups, whereas silver shunts do not. The 
routine use of these shunts would carry substantial costs savings. Antibiotic shunts should 
be the first choice for patients with hydrocephalus undergoing insertion of their first 
ventriculoperitoneal shunt. 
 
Panel: Research in context 
Evidence before this study 
A systematic review comparing antibiotic against standard shunts identified one randomised 
trial, one prospective cohort study and ten retrospective studies; none were adequately 
powered to detect a difference in infection rates. There were no randomised trials of silver 
versus standard shunts. Neurosurgeons were using antibiotic and silver shunts aiming to 
reduce infection despite a lack of firm evidence to support this and at increased financial 
cost. 
 
Added value of this study 
This is the largest randomised trial for ventriculoperitoneal shunts in hydrocephalus. 
Antibiotic shunts significantly reduce the risk of infection compared to standard shunts in all 
ages. Silver shunts have the same infection rate as standard shunts. From the perspective of 
the NHS healthcare system antibiotic shunts save £135,753 per infection avoided. 
 
Implications of the available evidence 
From both the patient perspective and that of the treating neurosurgeon, the hospital and 
the health service, every effort to reduce shunt infection should be made and health 
technologies such as impreganted shunts with their potential to reduce such infections 
deserve proper evaluation through appropriately planned and powered trials. Having 
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demonstrated a marked reduction in such infections, with all of the potentially catastrophic 
and life changing health sequalae that result from each infection, the BASICS trial has 
provided definitive evidence to support the adoption of antibiotic shunts in all patients 
having their first ventriculoperitoneal shunt in the UK. The increased up-front cost of the 
antibiotic shunt is offset by the added health economic benefit. The benefits and 
implications both from an efficacy and health economic point of view are most pronounced 
the younger the patient. The broader, global implications of these findings require 
consideration of generalizability across different healthcare systems. 
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Tables 
Table 1 
 Baseline patient characteristics and physical examination of the intention to treat population 
Baseline Characteristic Standard shunt Antibiotic shunt Silver shunt Total 
Patients randomised  536 538 531 1605 
Age at randomisation (years)     
N 536 538 531 1605 
Med (LQ - UQ) 42·5 (0·8 – 69·7) 43·9(1·1 – 70·8) 41·1 (0·5 – 68·8) 42·5 (0·8 – 69·6) 
(Min, Max) (0·0, 90·3) (0·0, 88·9) (0·0, 91·1) (0·0, 91·1) 
Age category, n (%)     
Paediatric 200 (37·3) 201 (37·4) 198 (37·3) 599 (37·3) 
Adult (<65 years) 174 (32·5) 156 (29·0) 172 (32·4) 502 (31·3) 
Adult (≥65 years) 162 (30·2) 181 (33·6) 161 (30·3) 504 (31·4) 
Gender, n (%)     
Female 246 (46·0) 260 (48·3) 282 (53·1) 788 (49·1) 
Male 289 (54·0) 278 (51·7) 249 (46·9) 816 (50·9) 
Missing 1 0 0 1 
Note: Med: Median; LQ: Lower Quartile; UQ: Upper Quartile; Min: Minimum; Max: Maximum 
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Table 2 
Summary of revisions, and reasons for revision, of first shunt according to catheter type and assessor 
 Standard shunt Antibiotic shunt Silver shunt Total 
 N % N % N % N % 
Summary of surgeries         
Randomised 536  538  531  1605  
Eligible for primary outcome (1) 533 99·4 535 99·8 526 99·4 1594 99·6 
   No shunt removal/revision 403 75·6 403 75·3 390 74·1 1196 75·0 
   Shunt removal/revision (for 
any cause) 
130 24·4 132 24·7 136 25·9 398 25·0 
         
Reason for revision as classified by central review     
Reason for revision         
   Revision for infection 32 6·0 12 2·2 31 5·9 75 4·7 
   Revision for other reason 
(no infection) 
98 18·4 120 22·4 105 20·0 323 20·3 
Type of infection      
Shunt CSF or peritoneal         
 30 
infection 
   Definite – Culture positive 22 68·8 6 50·0 25 80·6 53 70·7 
   Probable – Culture uncertain 1 3·1 0 0·0 2 6·5 3 4·0 
   Probable – Culture negative 3 9·4 3 25·0 1 3·2 7 9·3 
   Possible – Culture uncertain 1 3·1 0 0·0 1 3·2 2 2·7 
   Clinically classified infection 
(2) 
1 3·1 0 0·0 0 0·0 1 1·3 
Shunt deep incisional infection         
   Shunt deep incisional 
infection 
4 12·5 3 25·0 2 6·5 9 12·0 
         
Reason for shunt revision as classified by treating neurosurgeon  
   Suspected infection 33 6·2 15 2·8 30 5·7 78 4·9 
   Revision for other reason 
(no infection) 
97 18·2 117 21·9 106 20·2 320 20·1 
1 Randomised participants that did not receive a shunt (n=4) and had infection at time of insertion (n=7) were excluded from the 
primary outcome set, see Figure 2.  
2 Where the committee was unable to classify an infection, an infection was identified as reported on the case report forms. 
There was one case where the committee was unable to classify and this was clinically classified as an infection.  
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Table 3: Hazard ratio estimates from multivariate regression modelling  
Primary outcome          
Time to removal of the first 
shunt due to infection, as 
assessed by central review (1) 
Model estimate N events csHR (97·5% CI) P-value sHR (97·5% CI) P-value 
Shunt Standard 32 - - - - - - 
 Antibiotic 12 0·38 (0·18, 0·80) <0·01 0·38 (0·18, 0·80) <0·01 
 Silver 31 0·99 (0·56, 1·74) 0·96 0·99 (0·56, 1·72) 0·95 
Age group Paediatric 47 - - - - - - 
 Adult (<65 years) 23 0·55 (0·31, 0·97) 0·02 0·56 (0·32, 0·99) 0·02 
 Adult (≥65 years) 5 0·12 (0·04, 0·34) <0·01 0·12 (0·04, 0·35) <0·01 
          
Secondary outcomes          
Time to removal of the first 
shunt due to suspected 
infection, as assessed by 
treating neurosurgeon (1) 
Model estimate N events csHR (97·5% CI) P-value sHR (97·5% CI) P-value 
Shunt Standard 33 - - - - - - 
Antibiotic 15 0·45 (0·23, 0·91) 0·01 0·45 (0·23, 0·91) 0·01 
Silver 30 0·93 (0·53, 1·64) 0·77 0·92 (0·53, 1·61) 0·74 
Age group Paediatric 50 . . . . . . 
Adult (<65 years) 23 0·51 (0·29, 0·91) <0·01 0·53 (0·30, 0·93) 0·01 
Adult (≥65 years) 5 0·11 (0·04, 0·31) <0·01 0·12 (0·04, 0·33) <0·01 
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Time to removal/revision of the 
first shunt for any cause (1) 
Model estimate N events HR (97·5% CI) P-value    
Shunt Standard 130 . . .    
Antibiotic 132 1·01  (0·77, 1·33) 0·94    
Silver 136 1·08  (0·82, 1·42) 0·54    
Age group Paediatric 226 . . .    
Adult (<65 years) 118 0·57  (0·44, 0·74) <0·01    
Adult (≥65 years) 55 0·25  (0·18, 0·35) <0·01    
         
Time to failure of second shunt 
due to infection, following clean 
revision (2) 
Model estimate N events csHR (97·5% CI) P-value sHR (97.5% CI) P-value 
Shunt Standard 9 - - - - - - 
Antibiotic 6 0·55 (0·17, 1·81) 0·26 0·55 (0·17, 0·75) 0·25 
Silver 5 0·47 (0·13, 1·63) 0·17 0·48 (0·14, 1·67) 0·19 
Age group Paediatric 10 - - - - - - 
Adult (<65 years) 9 1·64 (0·58, 4·61) 0·28 1·72 (0·62, 4·81) 0·24 
Adult (≥65 years) 1 0·34 (0·03, 3·64) 0·14 0·37 (0·04, 3·91) 0·14 
csHR: Cause-specific hazard ratios from multivariate Cox model with infection as event of interest and both shunt and age group as covariates. 
sHR: Sub-distribution hazard ratios from multivariate Fine-Gray model with infection as event of interest, revision not for infection as a competing risk, and 
both shunt and age group as covariates. 
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HR: Hazard ratios from multivariate Cox model with revision/removal as event of interest and both shunt and age group as covariates. 
Follow up time (in months) summary statistics: Median; LQ - UQ; Min to Max: 
 1Follow up time from first shunt 22; 10-24; 0 to 24.  
 2Follow up time from second shunt following clean revision: 9; 2-19; 0 to 24. 
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Figures 
Figure 1 
CONSORT 2010 Flow Diagram 
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ITT: intention to treat 
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Figure 2 
Cumulative incidence plots of infection (top) and competing risk (bottom) by shunt type 
 
